Managed care perspective on three new agents for type 2 diabetes

Journal of Managed Care Pharmacy

Volumn 14, Issue 4, 2008, Pages 363-380

  VanDeKoppel, Shawna ^a   Choe, Hae Mi ^a   Sweet, Burgunda V ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANALGESIC AGENT; BIGUANIDE; EXENDIN 4; GENERIC DRUG; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING DRUG; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; UNINDEXED DRUG; VILDAGLIPTIN; WARFARIN;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADD ON THERAPY; ADJUVANT THERAPY; ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANOREXIA; ARTHRALGIA; BACKACHE; BEDTIME DOSAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIABETOGENESIS; DIARRHEA; DIET; DIZZINESS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EVENING DOSAGE; EXERCISE; FATIGUE; GASTROENTERITIS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIMB PAIN; LIVER TOXICITY; LONG TERM CARE; MEAL; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TERATOGENICITY; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 45949094989     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.4.363     Document Type: Review

References (56)

1. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;30(suppl):S12-S54.
2. Genath S. Diabetes mellitus. In: Federman DD, Dale DC, et al., eds. ACP Medicine. New York: WebMD Corporation; 2004.
3. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287:E199-E206.
4. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-30.
5. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45:1111-19.
6. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003; 46:3-19.
7. Young A. Amylin: physiology and pharmacology. Advances in Pharmacology. First ed. New York, NY: Elsevier; 2005.
8. Ludvik B, Thomaseth K, Nolan JJ, Clodi M, Prager R, Pacini G. Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects. Eur J Clin Invest. 2003;33:316-22.
9. Fineman M, Weyer C, Maggs DG, Strobel, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002;34:504-08.
10. Nathan DM. Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963-72.
11. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Pract. 2007;13:1-66. Available at: www.aace.com/pub/pdf/guidelines/ DMGuidelines2007.pdf. Accessed April 19, 2008.
12. Vijan S, Choe HM, Funnell MM, et al. Management of type 2 diabetes mellitus: University of Michigan Health System Guidelines for Clinical Care. Available at: http://cme.med.umich.edu/iCME/diabetesO4/. October 2007. Accessed December 19, 2007.
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
14. Turner RC, Cull CA, Frighi V, Holman R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-12.
15. UK Prospective Diabetes Study (UKPDS) Group. A randomized trial of efficacy of early addition of metformin in sulphonylurea-treated non-insulin dependent diabetes (UKPDS 28). Diabetes Care. 1998;21:87-92.
16. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27(1):141-47.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
18. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386-99.
19. Nathan DM. Finding new treatments for diabetes - how many, how fast... how good? N Engl J Med. 2007;356:437-40.
20. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals; February 2007.
21. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62:173-81.
22. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism. 2001;50:583-89.
23. Egan JM, Clocquet AR, Elahi D. The insulintropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002;87:1282-90.
24. Chen J, Couto FM, Minn AH, Shalev A. Exenatide inhibits β-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun. 2006;346:1067-74.
25. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003;26:2370-77.
26. Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther. 2005;7:467-76.
27. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-35.
28. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
29. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28:1083-91.
30. Zinman B, Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med. 2007;146:477-85.
31. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005;143:559-69.
32. Kim D, MacConnel L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487-93.
33. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta analysis. JAMA. 2007; 298:194-206. Available at: http://jama.ama-assn.org/cgi/reprint/298/2/ 194?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext= sitagliptin&searchid=1&FIRSTINDEX=0&resourcetype.HWCIT. Accessed Apri 27, 2008.
34. U.S. Food and Drug Administration. Exenatide (marketed as Byetta) information. FDA alert 10/2007. Available at: www.fda.gov/cder/drug/ infopage/exenatide/default.htm. Accessed October 29, 2007.
35. Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals; June 2005.
36. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002;4:51-61.
37. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes mellitus: a one year randomized controlled trial. Diabetes Care. 2003;26:784-90.
38. Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30:2794-99. Available at: http://care.diabetesjournals.org/cgi/content/full/30/11/2794. Accessed April 27, 2008.
39. Institute for Safe Medication Practices. Mg, mcg, units, mL: How will Symlin's safety measure up? Available at: www.ismp.org/Newsletters/ ambulatory/archives/200506_2. asp. June 2005. Accesssed June 28, 2007.
40. U.S. Food and Drug Administration. Symlin supplement approval. September 25, 2007. Available at: www.fda.gov/cder/foi/appletter/2007/ 021332s0061tr.pdf. Accessed April 13, 2008.
41. Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes. 2005;45:1100-07.
42. Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev. 2004; 20:55-60.
43. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; October 2007.
44. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612-19.
45. Anonymous. UPDATE 2-EU approves Novartis diabetes drug Galvus. Thomas Reuters. February 1, 2008. Available at: www.reuters.com/article/ companyNews/idUSL0116387320080201. Accessed April 19, 2008.
46. Hughes N. 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008;7:107-09.
47. Anonymous. Vildagliptin. Wikipedia. Available at: http://en.wikipedia.org/wiki/Vildagliptin. Accessed April 19, 2008.
48. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564-71.
49. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632-37.
50. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556-68.
51. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979-87.
52. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180-88.
53. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189-95.
54. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglilazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med. 2007;357:28-38.
55. Drugstore.com. Available at: www.drugstore.com/. Accessed April 19, 2008.
56. The Regence Group. Medication Policy Manual. Policy no. dru120, Byetta, exenaticle. May 29, 2007. Available at: http://blue.regence.com/ trgmedpol/drugs/dru120.pdf. Accessed April 27, 2008.